These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 28407996)

  • 1. A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.
    Li Y; Arellano AR; Bare LA; Bender RA; Strom CM; Devlin JJ
    Value Health; 2017 Apr; 20(4):547-555. PubMed ID: 28407996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
    Eccleston A; Bentley A; Dyer M; Strydom A; Vereecken W; George A; Rahman N
    Value Health; 2017 Apr; 20(4):567-576. PubMed ID: 28407998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective.
    Seguí MÁ; Crespo C; Cortés J; Lluch A; Brosa M; Becerra V; Chiavenna SM; Gracia A
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):889-99. PubMed ID: 25213317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
    Manchanda R; Patel S; Gordeev VS; Antoniou AC; Smith S; Lee A; Hopper JL; MacInnis RJ; Turnbull C; Ramus SJ; Gayther SA; Pharoah PDP; Menon U; Jacobs I; Legood R
    J Natl Cancer Inst; 2018 Jul; 110(7):714-725. PubMed ID: 29361001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of testing for breast cancer susceptibility genes.
    Holland ML; Huston A; Noyes K
    Value Health; 2009; 12(2):207-16. PubMed ID: 18647256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.
    Gamble C; Havrilesky LJ; Myers ER; Chino JP; Hollenbeck S; Plichta JK; Kelly Marcom P; Shelley Hwang E; Kauff ND; Greenup RA
    Ann Surg Oncol; 2017 Oct; 24(11):3116-3123. PubMed ID: 28699130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanding the criteria for BRCA mutation testing in breast cancer survivors.
    Kwon JS; Gutierrez-Barrera AM; Young D; Sun CC; Daniels MS; Lu KH; Arun B
    J Clin Oncol; 2010 Sep; 28(27):4214-20. PubMed ID: 20733129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Population-Based Multigene Testing for Breast and Ovarian Cancer Prevention.
    Guo F; Adekanmbi V; Hsu CD; Berenson AB; Kuo YF; Shih YT
    JAMA Netw Open; 2024 Feb; 7(2):e2356078. PubMed ID: 38353949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic Evaluation of Population-Based BRCA1 and BRCA2 Testing in Canada.
    Sun L; Wei X; Fierheller CT; Dawson L; Oxley S; Kalra A; Sia J; Feldman F; Peacock S; Schrader KA; Legood R; Kwon JS; Manchanda R
    JAMA Netw Open; 2024 Sep; 7(9):e2432725. PubMed ID: 39264630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.
    Phi XA; Greuter MJW; Obdeijn IM; Oosterwijk JC; Feenstra TL; Houssami N; de Bock GH
    Breast; 2019 Jun; 45():82-88. PubMed ID: 30904701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
    Saadatmand S; Tilanus-Linthorst MM; Rutgers EJ; Hoogerbrugge N; Oosterwijk JC; Tollenaar RA; Hooning M; Loo CE; Obdeijn IM; Heijnsdijk EA; de Koning HJ
    J Natl Cancer Inst; 2013 Sep; 105(17):1314-21. PubMed ID: 23940285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women.
    Patel S; Legood R; Evans DG; Turnbull C; Antoniou AC; Menon U; Jacobs I; Manchanda R
    Am J Obstet Gynecol; 2018 Apr; 218(4):431.e1-431.e12. PubMed ID: 29288066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
    Geuzinge HA; Obdeijn IM; Rutgers EJT; Saadatmand S; Mann RM; Oosterwijk JC; Tollenaar RAEM; de Roy van Zuidewijn DBW; Lobbes MBI; van 't Riet M; Hooning MJ; Ausems MGEM; Loo CE; Wesseling J; Luiten EJT; Zonderland HM; Verhoef C; Heijnsdijk EAM; Tilanus-Linthorst MMA; de Koning HJ;
    JAMA Oncol; 2020 Sep; 6(9):1381-1389. PubMed ID: 32729887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer.
    Müller D; Danner M; Schmutzler R; Engel C; Wassermann K; Stollenwerk B; Stock S; Rhiem K
    Eur J Health Econ; 2019 Jul; 20(5):739-750. PubMed ID: 30790097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers.
    Tuffaha HW; Mitchell A; Ward RL; Connelly L; Butler JRG; Norris S; Scuffham PA
    Genet Med; 2018 Sep; 20(9):985-994. PubMed ID: 29300376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs and benefits of diagnosing familial breast cancer.
    Heimdal K; Maehle L; Møller P
    Dis Markers; 1999 Oct; 15(1-3):167-73. PubMed ID: 10595273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.
    Plevritis SK; Kurian AW; Sigal BM; Daniel BL; Ikeda DM; Stockdale FE; Garber AM
    JAMA; 2006 May; 295(20):2374-84. PubMed ID: 16720823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer.
    Manchanda R; Sun L; Sobocan M; Rodriguez IV; Wei X; Kalra A; Oxley S; Sideris M; Fierheller CT; Morgan RD; Chandrasekaran D; Rust K; Spiliopoulou P; Miller RE; Crusz SM; Lockley M; Singh N; Faruqi A; Casey L; Brockbank E; Phadnis S; Mills-Baldock T; El-Khouly F; Jenkins LA; Wallace A; Ahmed M; Kumar A; Swisher EM; Gourley C; Norquist BM; Evans DG; Legood R
    J Natl Compr Canc Netw; 2024 Apr; 22(2 D):. PubMed ID: 38866043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry.
    Manchanda R; Patel S; Antoniou AC; Levy-Lahad E; Turnbull C; Evans DG; Hopper JL; Macinnis RJ; Menon U; Jacobs I; Legood R
    Am J Obstet Gynecol; 2017 Nov; 217(5):578.e1-578.e12. PubMed ID: 28690137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of incorporating a hypothetical DCIS prognostic marker into breast cancer screening.
    Trentham-Dietz A; Ergun MA; Alagoz O; Stout NK; Gangnon RE; Hampton JM; Dittus K; James TA; Vacek PM; Herschorn SD; Burnside ES; Tosteson ANA; Weaver DL; Sprague BL
    Breast Cancer Res Treat; 2018 Feb; 168(1):229-239. PubMed ID: 29185118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.